143
EMA’s Committee for Medicinal Products for Human Use (CHMP) has initiated an evaluation procedure for Vidprevtyn, a vaccine against Covid-19 developed by Sanofi Pasteur. The CHMP’s decision is based on the preliminary results of laboratory studies (non-clinical data) and of the first clinical studies in adults, which suggest that the vaccine is able to trigger the production of antibodies that affect Sars-CoV-2, the virus that causes Covid-19 and can help protect against the disease. The EMA will evaluate the data as it becomes available to decide if the benefits outweigh the risks.